Kymera Therapeutics (NASDAQ: KYMR) reported Q2 2026 collaboration revenue of $65.0 million, up from $11.5 million a year earlier, while basic and diluted net loss per share narrowed to $0.62 from $0.95. Milestone revenue reduced the quarterly loss despite higher research spending, while early enrollment completion moved the KT-621 atopic dermatitis data readout forward to year-end 2026.
Core Financial Results
Revenue consisted entirely of two collaboration payments: a $45 million option exercise fee from Gilead Sciences and a $20 million milestone from Sanofi. At the same time, operating expenses increased as Kymera invested in its STAT6 program, discovery platform, and R&D organization.
Higher collaboration revenue more than offset the increase in operating expenses, narrowing both operating and net losses from the prior-year quarter.
| Metric | Q2 2026 | Q2 2025 | Year-over-year change |
|---|---|---|---|
| Collaboration revenue | $65.0 million | $11.5 million | Up about 466% |
| R&D expenses | $119.5 million | $78.4 million | Up about 52% |
| G&A expenses | $21.1 million | $17.6 million | Up about 20% |
| Total operating expenses | $140.6 million | $96.0 million | Up about 46% |
| Operating loss | $75.6 million | $84.6 million | Loss narrowed about 11% |
| Net loss | $61.2 million | $76.6 million | Loss narrowed about 20% |
| Basic and diluted net loss per share | $0.62 | $0.95 | Loss per share narrowed about 35% |
Interest and other income also increased to $14.5 million from $8.1 million, further reducing the difference between operating loss and net loss.
Pipeline and Collaboration Progress
KT-621 produced the quarter’s most consequential clinical update. Enrollment in the BROADEN2 Phase 2b atopic dermatitis trial finished nearly six months earlier than originally planned, allowing Kymera to bring the expected topline data release forward from mid-2027 to year-end 2026.
The company also advanced its wholly owned KT-579 program and recorded collaboration milestones tied to programs controlled by Sanofi and Gilead.
| Program | Development status | Next disclosed milestone |
|---|---|---|
| KT-621 BROADEN2 in atopic dermatitis | Phase 2b enrollment completed nearly six months early | Topline data by year-end 2026; Phase 3 planned by mid-2027, subject to regulatory discussions |
| KT-621 BREADTH in asthma | Phase 2b enrollment ongoing | Data expected in late 2027 |
| KT-579 in healthy volunteers | Phase 1 enrollment ongoing | Data expected in Q4 2026; lupus proof-of-concept trial planned afterward |
| KT-485 with Sanofi | First-in-human Phase 1 trial initiated | Sanofi is leading development, regulatory, and commercial work |
| KT-200 with Gilead | Gilead exercised its exclusive license option | IND-enabling work planned to support an IND filing in 2027 |
In a Phase 1 study involving healthy Japanese adults, KT-621 achieved median blood STAT6 degradation of at least 98% at both tested dose levels. Kymera said the pharmacokinetic, safety, and tolerability findings were consistent with results from non-Japanese healthy adults and atopic dermatitis patients, although these early-stage findings do not establish Phase 2 efficacy.
Milestone Revenue Offset Heavier R&D Spending
Collaboration revenue increased by approximately $53.5 million year over year, while operating expenses rose by about $44.6 million. That relationship explains why operating loss narrowed by roughly $9.0 million even though R&D spending increased substantially.
The improvement was driven by specific collaboration events rather than commercial product sales. The $45 million Gilead payment was tied to its KT-200 option exercise, while the $20 million Sanofi payment followed dosing of the first participant in the KT-485 Phase 1 trial. Consequently, future quarterly revenue remains dependent on the timing and achievement of collaboration events as Kymera continues funding its clinical pipeline.
Liquidity and Balance Sheet
Kymera ended June 2026 with $1.505 billion in cash, cash equivalents, and marketable securities, compared with $1.619 billion at the end of December 2025. The balance declined by approximately $114.5 million, or 7%, during the first half of 2026.
Management expects the available capital to fund operations into 2029 and beyond multiple planned clinical milestones. The June balance sheet also included a $20 million account receivable related to the Sanofi milestone, which was earned in Q2 and collected in Q3.
Recent Insider Transactions
The supplied insider-transaction data identifies no open-market purchases during the latest six-month period. Among the 10 most recent listed transactions, six were sales, three were conversions of derivative securities, and one was a stock grant.
| Date | Insider | Role | Transaction | Reported value |
|---|---|---|---|---|
| Jul. 27, 2026 | Terence Rooney | Officer | Stock award at $0.00 | $0 |
| Jul. 7, 2026 | Nello Mainolfi | CEO | Sale at $119.00 | $5.95 million |
| Jul. 7, 2026 | Nello Mainolfi | CEO | Derivative conversion at $2.08 | $104,000 |
| Jul. 1, 2026 | Nello Mainolfi | CEO | Sale at $112.80–$116.56 | $9.22 million |
| Jul. 1, 2026 | Noah Goodman | Officer | Sale at $114.29 | $387,329 |
| Jul. 1, 2026 | Nello Mainolfi | CEO | Derivative conversion at $2.08 | $166,400 |
| Jun. 30, 2026 | Bruce N. Jacobs | CFO | Sale at $110.54–$117.70 | $8.86 million |
| Jun. 30, 2026 | Bruce N. Jacobs | CFO | Derivative conversion at $5.33 | $327,145 |
| Jun. 26, 2026 | BVF Partners L.P. | Affiliated person | Sale at $106.50 | $173.67 million |
| Jun. 25, 2026 | Noah Goodman | Officer | Sale at $109.00–$119.00 | $570,000 |
These transactions establish the direction and scale of recent insider activity but do not, on their own, explain the sellers’ motivations or views on Kymera’s prospects.
Risks Investors Need to Watch
- Clinical results remain the central risk. Early STAT6 degradation and safety findings may not predict the efficacy or safety results from the BROADEN2 Phase 2b trial.
- Revenue is tied to collaboration events. All Q2 revenue came from the Gilead option fee and Sanofi milestone, so quarterly revenue can vary with partner decisions and development achievements.
- Pipeline investment is increasing losses and capital requirements. R&D expenses rose about 52% year over year, and Kymera still recorded a $61.2 million quarterly net loss despite the milestone revenue.
- Timelines depend on regulators and partners. The planned KT-621 Phase 3 start is subject to regulatory discussions, while Sanofi and Gilead control important development work for partnered programs.
Summary
Kymera’s Q2 2026 loss narrowed because $65 million of collaboration revenue offset a substantial increase in R&D spending. The most important operating development was the accelerated KT-621 atopic dermatitis timeline, with Phase 2b data now expected by year-end 2026. Investors’ next focus is whether those results support the planned Phase 3 transition, while Kymera’s $1.5 billion liquidity position provides funding into 2029 as multiple programs advance.
Find out more
Comments